BNLI Randomised trial of Radiation dose in Non-Hodgkin's Lymphoma (NHL)
ISRCTN | ISRCTN71826974 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN71826974 |
Secondary identifying numbers | RADIATION |
- Submission date
- 19/08/2002
- Registration date
- 19/08/2002
- Last edited
- 18/10/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr - -
Scientific
Scientific
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | BNLI Randomised trial of Radiation dose in Non-Hodgkin's Lymphoma (NHL) |
Study objectives | Not provided at time of registration |
Ethics approval(s) | Not provided at time of registration |
Health condition(s) or problem(s) studied | Lymphoma (non-Hodgkin's) |
Intervention | Standard radiotherapy versus low dose radiotherapy |
Intervention type | Other |
Primary outcome measure | Not provided at time of registration |
Secondary outcome measures | Not provided at time of registration |
Overall study start date | 30/04/1997 |
Completion date | 31/12/2005 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 1000 |
Key inclusion criteria | 1. Any patient receiving local radiotherapy (RT) where the aim of the treatment is local control of that lymphoma, whether as radical treatment of Stage I disease, consolidation therapy after chemotherapy or palliation 2. Histological diagnosis of NHL 3. Aged 18 years or over 4. Able to give informed consent |
Key exclusion criteria | Not provided at time of registration |
Date of first enrolment | 30/04/1997 |
Date of final enrolment | 31/12/2005 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
MRC Clinical Trials Unit
London
NW1 2DA
United Kingdom
NW1 2DA
United Kingdom
Sponsor information
British National Lymphoma Investigation (BNLI) (UK)
Charity
Charity
CRC and UCL Cancer Trials Centre
222 Euston Road
London
NW1 2DA
United Kingdom
Phone | +44 (0)20 7679 8060 |
---|---|
bnli@ctc.ucl.ac.uk | |
Website | http://www.bnli.ucl.ac.uk |
Funders
Funder type
Charity
British National Lymphoma Investigation (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Plain English results | No | Yes |
Editorial Notes
18/10/2018: Cancer Research UK lay results summary link added to Results (plain English)
11/01/2016: no publications found on PubMed.